NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $0.50 +0.00 (+0.82%) As of 01:41 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neumora Therapeutics Stock (NASDAQ:NMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$0.47▼$0.5350-Day Range$0.50▼$1.7352-Week Range$0.47▼$3.65Volume1.01 million shsAverage Volume1.69 million shsMarket Capitalization$94.70 millionP/E RatioN/ADividend YieldN/APrice Target$6.57Consensus RatingModerate Buy Company Overview Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the brain. The company combines neuroscience research with data science, including its proprietary MAP platform, to identify patient subgroups, discover potential drug targets and support the development of therapies for neurological and neuropsychiatric conditions. Neumora’s lead investigational product is navacaprant, an oral, selective kappa opioid receptor antagonist being evaluated for major depressive disorder. The company is also advancing additional programs aimed at conditions such as schizophrenia and other brain disorders. These products remain investigational and have not been approved for commercial use unless authorized by applicable regulatory agencies. Neumora was founded in 2019 through a collaboration involving ARCH Venture Partners and Amgen and is headquartered in Watertown, Massachusetts. The company became publicly traded on the Nasdaq under the symbol NMRA in 2023. Its operations and clinical development activities are primarily focused on the United States and international clinical-trial markets.AI Generated. May Contain Errors. Read More Neumora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNMRA MarketRank™: Neumora Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 223rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeumora Therapeutics has a consensus price target of $6.57, representing about 1,277.7% upside from its current price of $0.48.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neumora Therapeutics are expected to grow in the coming year, from ($0.83) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.08% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 9.02.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 13.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest2 people have searched for NMRA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,219.00 in company stock.Percentage Held by Insiders26.94% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMRA Stock News HeadlinesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $6.57 Average Price Target from AnalystsSeptember 24, 2026 | americanbankingnews.comNeumora Therapeutics, Inc. (NMRA)September 15, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 5 at 1:00 AM | Profits Run (Ad)Top Neumora Executive Makes Notable Move With Insider Stock SaleAugust 21, 2026 | tipranks.comNeumora Therapeutics Announces CEO Transition and Q2 ResultsAugust 14, 2026 | tipranks.comNeumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comNeumora Therapeutics Shares Rise on Positive Obesity Drug ResultsJuly 28, 2026 | marketwatch.comNeumora advances NMRA-215 with positive toxicology resultsJuly 27, 2026 | tipranks.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $1.79 on January 1st, 2026. Since then, NMRA stock has decreased by 73.4% and is now trading at $0.4770. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $16.00-$18.00 per share. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP). Company Calendar Last Earnings8/14/2026Today10/05/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, NMRA's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NMRA CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees63Year Founded2020Price Target and Rating Average Price Target for Neumora Therapeutics$6.57 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+1,203.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$236.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-242.28% Return on Assets-131.32% Debt Debt-to-Equity Ratio1.19 Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book0.81Miscellaneous Outstanding Shares187,900,000Free Float137,277,000Market Cap$94.70 million OptionableOptionable Beta2.95 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:NMRA) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
